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Abstract
Background:  This study was designed to evaluate the effect of recombinant human thrombin (rThrombin)
concentration on time to hemostasis (TTH), clot durability, and clot strength in settings that replicate the heparinization
and platelet inhibition often found in surgical populations.
Methods:  A modified, anticoagulated rabbit arteriovenous shunt preparation was selected to model vascular
anastomotic bleeding. Rabbits were treated with heparin or heparin + clopidogrel and TTH was measured after applying
a range of topical rThrombin concentrations or placebo, in combination with absorbable gelatin sponge, USP. Treatments
(placebo, rThrombin) were randomly assigned and the investigator was blinded to treatment. TTH was evaluated with
the Kaplan-Meier method. After hemostasis was achieved, clot burst assessment was performed for
heparin + clopidogrel treated animals. Clot viscoelastic strength and kinetics were measured in ex-vivo samples using
thromboelastography (TEG) methods.
Results: TTH decreased with increasing concentrations of rThrombin in heparin-treated animals and was shorter after
treatment with 1000 IU/mL rThrombin (73 seconds) than with 125 IU/mL rThrombin (78 seconds; p = 0.007). TTH also
decreased with increasing concentrations of rThrombin in heparin + clopidogrel treated animals; again it was significantly
shorter after treatment with 1000 IU/mL rThrombin (71 seconds) than with 125 IU/mL rThrombin (177 seconds;
p < 0.001). Variability in TTH was significantly smaller after treatment with 1000 IU/mL rThrombin than after 125 IU/mL
rThrombin, indicating greater reliability of clot formation (p < 0.001 for heparin or heparin + clopidogrel treatments).
Clot durability was examined in heparin + clopidogrel treated animals. Clots formed in the presence of 1000 IU/mL
rThrombin were significantly less likely to rupture during clot burst assessment than those formed in the presence of
125 IU/mL rThrombin (0% versus 79%, p < 0.001). In vitro clot strength and clot kinetics, as determined by TEG in
heparin + clopidogrel samples, were positively associated with the amount of rThrombin activity added for clot initiation.
Conclusion: In an animal model designed to replicate the anti-coagulation regimens encountered in clinical settings,
topical rThrombin at 1000 IU/mL more reliably controlled the pharmacological effects of heparin or
heparin + clopidogrel on hemostasis than rThrombin at 125 IU/mL. Results from in vitro assessments confirmed a
positive relationship between the amount of rThrombin activity and both the rate of clot formation and clot strength.
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Background
In the study described herein, a rabbit model of arterial
anastomotic bleeding was used to examine the effect of
recombinant human thrombin (rThrombin) concentra-
tion on time to hemostasis (TTH) under varying condi-
tions of pharmacologic anticoagulation and platelet
inhibition.
Thrombin has been widely used as a topical hemostatic
agent during surgical procedures since the 1940s [1,2].
The efficacy of topical thrombin at a concentration of
1000 IU/mL was recently demonstrated in clinical trials,
although no clinical trials have compared the effects of
different concentrations of topical thrombin on hemo-
static efficacy [3-5]. The critical role of thrombin concen-
tration in fibrin clot formation has been demonstrated in
a number of in vitro settings; clots formed in the presence
of higher concentrations of thrombin had more tightly
packed fibrin strands and were more resistant to fibrinol-
ysis, when compared with clots formed in the presence of
lower concentrations of thrombin [6-8]. In animal mod-
els, TTH was dependent on rThrombin concentration; for
example, gauze soaked in rThrombin at concentrations
from 500 to 2000 IU/mL stopped bleeding significantly
faster in a rabbit model of hepatic bleeding than gauze
soaked with rThrombin 100 IU/mL [9,10]. In another
study, 125 IU/mL human plasma-derived thrombin did
not appear to be an adequate concentration for establish-
ing durable clots in a healthy porcine model of liver injury
[11]. In that study, human plasma-derived thrombin
(125 IU/mL) with an absorbable gelatin sponge (AGS)
improved the incidence of hemostasis compared to saline
with AGS. However, rebleeding was also observed at a
number of sites during the 12 minute evaluation period,
thus thrombin at 125 IU/mL did not appear to be an ade-
quate concentration for establishing durable clots.
Although there is substantial inter-species heterogeneity
in coagulation capacity, collectively these results suggest
that there is an optimum concentration of topical
thrombin needed at the wound for rapid TTH and durable
clotting.
Clopidogrel is a potent platelet function inhibitor and is
widely prescribed, ranking second in a 2008 list of world-
wide pharmaceutical sales [12]. There are a wide variety of
opinions regarding the timing for discontinuing clopidog-
rel before undergoing a surgical procedure. After recent
reports of rebound cardiac risk for 90 days following
abrupt discontinuation of clopidogrel, it has been argued
that stopping clopidogrel in patients with a high risk of
perioperative myocardial infarction may affect the inci-
dence of perioperative cardiac events [13]. As a conse-
quence, increasing numbers of patients are presenting for
emergent, urgent, or elective surgical procedures with sig-
nificant clopidogrel platelet inhibition as a result of a
reluctance or inability to withhold clopidogrel prior to
surgery. The effect of anti-platelet medications on TTH has
not been thoroughly evaluated, although recent clinical
trial data suggested that TTH was delayed in patients being
treated for conditions for which anti-platelet medications
are commonly-used when compared with patients who
were receiving treatment for conditions for which anti-
platelet medications are less-commonly used [14].
Based on the observations described above, we hypothe-
sized that adoption of the standard 1000 IU/mL
thrombin concentration gained acceptance in clinical
practice over the last 50 years because of its observed effi-
cacy over a range of clinical settings. Although thrombin
is a remarkably potent effector of hemostasis, the condi-
tions in which exogenous thrombin is applied vary
widely, with differences in blood flow, the amount of
hemodilution, and the presence or absence of pharmaco-
logical anticoagulation agents. Considering these varia-
bles, one would predict that topical thrombin applied at
lower concentrations may be ineffective in some clinical
settings.
In this study, the effect of rThrombin concentration on
TTH under varying conditions of pharmacologic anticoag-
ulation and platelet inhibition was evaluated by perform-
ing in vivo experiments with a range of thrombin
concentrations in a model of arterial anastomotic bleed-
ing, in rabbits treated with heparin or with
heparin + clopidogrel. Reliability of clot formation was
assessed by examining variability in TTH. After hemostasis
was achieved, we examined differences in clot durability
resulting from various concentrations of rThrombin by
evaluating clot burst in animals treated with
heparin + clopidogrel. We also performed an in vitro
assessment of clot strength and the rate of clot formation
by adding different amounts of rThrombin activity to
heparin + clopidogrel rabbit blood samples, and evaluat-
ing the viscoelastic properties of the clot using modified
thromboelastography (TEG) [15].
Methods
Animals
Female New Zealand White rabbits (Charles River Labora-
tories, Hollister, CA), weighing 2.0 to 3.8 kg and approxi-
mately 12 weeks of age, were used for these studies. Six
animals were used in each study. Animals were acclimated
to the facility for 7 to 10 days before the surgical proce-
dure and were maintained in good condition. All animal
studies were performed under approved protocols in
accordance with the Guide for the Care and Use of Labo-
ratory Animals (US DHHS publication NIH 86-23).Annals of Surgical Innovation and Research 2009, 3:14 http://www.asir-journal.com/content/3/1/14
Page 3 of 9
(page number not for citation purposes)
In Vivo Study Design
Clinical vascular anastomotic bleeding was simulated in a
rabbit arteriovenous (AV) shunt model. The experimental
design evaluated the dependence of TTH on the applied
rThrombin concentration in the presence of hepariniza-
tion, both with and without clopidogrel platelet inhibi-
tion. All rThrombin concentrations were applied using an
AGS. Anticoagulation with heparin was used in this
model in order to maintain shunt patency. An initial
study, evaluating several rThrombin concentrations
(31.25, 62.5, 125, and 1000 IU/mL) or placebo, was per-
formed in rabbits treated with heparin. In further studies,
hemostasis was evaluated in rabbits treated with
heparin + clopidogrel using two concentrations of
rThrombin (125 and 1000 IU/mL) or placebo. The inves-
tigator was blinded to treatment during the procedure and
at the time of hemostasis evaluation, and treatment (pla-
cebo, rThrombin) was randomly assigned.
Multiple measurements of TTH were performed on each
rabbit. Each measurement was performed on a new poly-
tetrafluoroethylene (PTFE) graft. In the initial study of
rabbits treated with heparin, 12 grafts were evaluated for
placebo and 8 grafts were evaluated for each rThrombin
concentration. In the heparin + clopidogrel treated rab-
bits, 10 grafts were evaluated for placebo and 14 grafts
were evaluated for each rThrombin concentration. For
each graft, physiological parameters critical to hemostasis
(i.e., model control parameters) were measured. These
included body weight, activated partial thromboplastin
time (aPTT; measured at baseline and after heparin treat-
ment), body temperature, blood flow, and mean arterial
pressure (MAP). Comparability of these parameters was
used to demonstrate consistency among animals and
standardization between grafts, and was necessary in
order to consider each measure of TTH in an individual
graft as an independent observation.
Treatments: rThrombin, Placebo, and Absorbable Gelatin 
Sponge
On the day of the AV graft procedure, a 5000 IU vial of
rThrombin (RECOTHROM®, ZymoGenetics, Inc., Seattle,
WA) was reconstituted in 5 mL of sterile saline, yielding a
1000 IU/mL rThrombin solution. The 1000 IU/mL solu-
tion was diluted with placebo to yield 31.25 IU/mL,
62.5 IU/mL, and 125 IU/mL rThrombin solutions. Pla-
cebo solution consisted of the excipients contained in the
formulation for rThrombin [16]. AGS (Gelfoam, Pharma-
cia & Upjohn Company, Kalamazoo, MI, size 100) was
cut into 2 × 4 × 1 cm strips and combined with rThrombin
or placebo solutions in accordance with the instructions
in the rThrombin package insert. The median final vol-
ume of rThrombin or placebo mixed per sponge was
0.762 mL (range 0.756-0.775 mL).
Clopidogrel Administration
Animals received 20 mg/kg oral doses of clopidogrel
bisulfate (Plavix®, Bristol-Meyers Squibb/Sanofi Aventis,
Bridgewater, NJ) once daily for three days prior to AV
shunt placement and hemostasis evaluation. A 75 mg
clopidogrel tablet was dissolved in 3 mL of sterile water.
Each animal received between 1.6 and 2.2 mL of the
25 mg/mL solution per day by gavage. Surgical procedures
were performed 2 hours after the final dose of clopidogrel.
Rabbit AV Shunt Procedure
AV shunts were surgically created by using a modification
of methods previously described [17]. Briefly, rabbits
were immobilized with ketamine hydrochloride (Fort
Dodge Animal Health, Ft. Dodge, IA; 50 mg/kg, intramus-
cular injection), and anesthesia was maintained using
inhaled isoflurane (1% to 2%). The animals were placed
on a water-jacketed heating pad maintained at 37°C dur-
ing the experimental period and core body temperature
was monitored. The animal's right femoral artery was can-
nulated for measurement of mean arterial pressure (MAP)
and the left femoral vein was cannulated for heparin
administration. An AV shunt that linked the blood flow of
the left carotid artery and the right jugular vein was cre-
ated by isolating and cannulating these vessels with a 3 to
4 cm length of Micro-Renathane tubing (MRE 080, 0.080"
O.D. × 0.040" I.D., Braintree Scientific, Braintree, MA)
connected to a 15 cm length of silicone catheter tubing (7-
French, 0.078" I.D. × 0.125" O.D., Access Technologies,
Skokie, IL). The catheters were exteriorized and connected
with a 2 to 2.5 cm PTFE graft segment (3 mm, SN AFEP
7108, Bard Peripheral Vascular Incorporated, Tempe, AZ).
Blood flow through the shunt was measured using a Tran-
sonic System Incorporated Flowmeter, model TS410 (Ith-
aca, NY). Each rabbit received 100 U/kg heparin (Abraxis
Pharmaceutical Products, Schaumburg, IL) by intrave-
nous (IV) bolus injection, followed by a continuous 50 U/
kg/mL infusion of heparin at a flow rate of 5 mL/hr via the
femoral vein; aPTT was measured prior to heparin treat-
ment and 5-10 minutes after IV heparin bolus.
Suture Hole Bleed and Measurement of TTH
To achieve consistent conditions between AV grafts, MAP
was maintained at approximately 55 mm Hg (+/- 2 mm
Hg) by adjusting depth of anesthesia, and aPTT was main-
tained at a value > 400 seconds by heparin infusion.
Suture hole bleeding was assessed by puncturing the
center section of the PTFE graft segment with two 18 inch
silk suture needles (4-0 needles; reverse cutting needle
size P-3, stock number 641G, Ethicon Incorporated,
Somerville, NJ), creating 4 needle holes. The AGS contain-
ing 0.77 mL of rThrombin or placebo was immediately
wrapped around the graft, completely covering the bleed-
ing surfaces (suture holes). The wetted AGS was then cov-
ered with gauze sponges, and continuous digital pressureAnnals of Surgical Innovation and Research 2009, 3:14 http://www.asir-journal.com/content/3/1/14
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was applied. After 60 seconds the gauze sponges were vis-
ually inspected for bleeding. If cessation of bleeding had
not occurred, new gauze sponges were applied with digital
pressure and this process was repeated until no visible
blood was observed on the gauze sponges. TTH was
recorded in seconds. If TTH was not achieved within
300 seconds, the experiment was terminated. At the con-
clusion of the assessment period, the catheters were
clamped, flushed with saline, the PTFE segment was
removed, and a fresh PTFE segment was inserted. Baseline
measurements were obtained for MAP, core temperature,
and aPTT. Additional heparin (50 U/kg, IV bolus) was
injected as needed to maintain an aPTT > 400 seconds. If
a MAP of 55 mm Hg could not be maintained by adjust-
ing the depth of anesthesia, the animal was euthanized.
Suture Hole Clot Burst Assessment
In the rabbits treated with heparin + clopidogrel, clot
burst at the suture needle puncture sites was assessed after
the 300 second assessment of TTH, if hemostasis had
been achieved. The procedure involved clamping off
blood flow to the jugular vein catheter approximately 2-
3 cm downstream from the AV shunt graft for a period of
10 seconds. Complete obstruction of blood flow created
an increase in blood pressure at the site of the blood clot.
Clot burst observation during the 10 second period was
recorded as either positive (blood seeped through the AGS
onto the gauze sponge) or negative (no seepage was
observed). Clot burst was not assessed in rabbits treated
with heparin alone.
In Vitro Study Design
The viscoelastic properties of blood clots were assessed in
ex-vivo blood samples. TEG was used to measure the
mechanical resistance to clot formation as a function of
time and provided an in vitro correlate for the effects of
rThrombin concentration on the rate of clot formation
and clot strength.
TEG Samples from Rabbit AV Shunt Model
Blood samples from the central ear artery were collected in
citrate. For the 3 rabbits evaluated, a sample was collected
2 hours after clopidogrel dosing and heparin (1 U/mL)
was added ex vivo. The citrated rabbit blood was recalci-
fied according to a standard protocol with 0.2 M CaCl2
plus normal saline just prior to the TEG assay (Haemo-
scope Corporation, Niles, IL). The blood clotted within
normal parameters for rabbit blood without exogenous
rThrombin. A modified method for rThrombin clot initi-
ation was empirically derived and covered a ten-fold
range of rThrombin enzymatic activity (0.76 to 6.1 IU
added per mL of rabbit blood).
Thromboelastograph Parameters
TEG measures clot viscoelastic properties by recording
mechanical resistance to clot formation as a function of
time.
￿ The rate of clot formation (i.e., development of the
fibrin matrix, factor XIII cross-linking, platelet incor-
poration, and platelet aggregation) is obtained by
measuring the alpha angle (α) [15]. The α is derived
from the slope of the maximum amplitude (MA) of
the measured resistance to clot formation vs. time.
￿ Clot firmness or strength is measured by the MA and
is highly influenced by platelet number and function
[15]. Clot strength (shear elastic modulus) is repre-
sented by G and is calculated from the amplitude.
Maximum clot strength is derived as follows:
The relationships between both the rate of clot formation
(α) and clot strength (Gmax) and the amount of
rThrombin activity added for clot initiation were assessed.
Statistical Analyses
Statistical analyses are described below for each experi-
ment and were performed using SAS software (version
9.2, SAS Institute Inc., Cary, NC). Statistical significance
was defined as p-values < 0.05. The number of grafts per
treatment group was not based on formal sample size cal-
culations or statistical power.
Comparison of TTH
Each measurement of TTH in an individual graft was con-
sidered an independent measurement. That is, the experi-
mental system (rabbit and shunt) was considered uniform
except for the presence or absence of clopidogrel. The
effect of different rThrombin concentrations on TTH was
evaluated with the Kaplan-Meier method. Comparisons
of TTH between different concentrations of rThrombin
were performed using the log-rank test. TTH times of >
300 seconds were censored.
Variability of TTH
The reliability of hemostasis onset observed after treat-
ment with 125 IU/mL or 1000 IU/mL rThrombin was
compared for rabbits treated with heparin and for rabbits
treated with heparin + clopidogrel by analyzing the varia-
bility in TTH. Hypotheses of equal variability in TTH for
rThrombin concentrations of 125 IU/mL and 1000 IU/
mL were tested using the folded F-test.
Incidence of Clot Burst
After hemostasis had been achieved, we examined poten-
tial differences in clot durability induced by different con-
G dynes cm MA MA max(/ ) [ / ( ) ] / .
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centrations of rThrombin by evaluating clot burst in
rabbits treated with heparin + clopidogrel. Fisher's exact
test was used to compare the difference in incidence of
clot burst after treatment with 125 IU/mL or 1000 IU/mL
rThrombin.
In Vitro TEG Assays
Raw TEG data are presented. Pearson correlation coeffi-
cients were calculated to assess the relationship between
the amount of rThrombin added and the rate of clot for-
mation and clot strength.
Results
In Vivo Experiments
A strong concentration-dependent effect of rThrombin on
TTH was observed in an initial study in rabbits treated
with heparin. Kaplan-Meier estimates of median TTH val-
ues were 73 seconds (1000 IU/mL rThrombin),
78 seconds (125 IU/mL), 133 seconds (62.5 IU/mL),
214 seconds (31.25 IU/mL), and > 265 seconds (pla-
cebo). Median TTH for the placebo group could not be
determined because hemostasis was not achieved before
the end of the observation period for half of the 12 grafts
(i.e., half the TTH values were > 300 seconds). TTH
decreased significantly with increasing rThrombin con-
centration (p < 0.001). A pairwise log-rank test revealed
that TTH after treatment with 1000 IU/mL rThrombin
(median 73 seconds; 95% CI: 65, 75) was shorter than
after treatment with 125 IU/mL rThrombin (median
78 seconds; 95% CI: 70, 95; p = 0.007). In addition, the
reliability of hemostasis onset achieved in grafts treated
with 1000 IU/mL rThrombin was greater than that
observed in grafts treated with 125 IU/mL rThrombin, as
indicated by reduced variability in TTH at the 1000 IU/mL
rThrombin concentration in heparin treated animals (p <
0.001).
A concentration dependent effect of rThrombin on TTH
was also observed in subsequent studies in rabbits treated
with heparin + clopidogrel (Figure 1). Kaplan-Meier esti-
mates of median TTH were 71 seconds (1000 IU/mL
rThrombin), 177 seconds (125 IU/mL), and 271 seconds
(placebo). TTH decreased significantly with increasing
rThrombin concentration (p < 0.001). A pairwise log-
rank test revealed that TTH was significantly shorter after
treatment with 1000 IU/mL (median 71 seconds; 95% CI:
65, 77) than after treatment with 125 IU/mL rThrombin
(median 177 seconds; 95% CI: 127, 218; p <  0.001).
Looking specifically at the response to 1000 IU/mL
rThrombin, median TTH was similar for both treatment
regimens (heparin: 73 seconds; heparin + clopidogrel:
71 seconds; p = 0.52). In contrast, median TTH in grafts
treated with 125 IU/mL rThrombin was prolonged after
heparin + clopidogrel treatment (177 seconds) compared
with heparin treatment alone (78 seconds; p < 0.001).
The reliability of hemostasis onset achieved in grafts
treated with 1000 IU/mL rThrombin was greater than that
observed in grafts treated with 125 IU/mL rThrombin, as
indicated by reduced variability in TTH at the 1000 IU/mL
rThrombin concentration in heparin + clopidogrel treated
animals (p < 0.001; Figure 2). Variability in the placebo
group could not be estimated because hemostasis was not
achieved before the end of the observation period for all
of the grafts (i.e., some TTH values in the placebo group
were > 300 seconds).
Clot durability was assessed in animals treated with
heparin + clopidogrel. In these studies, multiple consecu-
tive AV shunt grafts were placed and different topical
rThrombin or placebo treatments were administered in
each animal. The durability of clots formed in grafts
treated with 1000 IU/mL rThrombin was greater than that
observed in grafts treated with 125 IU/mL rThrombin, as
indicated by reduced incidence of clot burst. Clots that
formed in the presence of 1000 IU/mL rThrombin were
significantly less likely to rupture during clot burst assess-
ment (0% of clots ruptured) than those formed in the
Kaplan-Meier estimates for the probability of bleeding after  treatment with different concentrations of rThrombin or pla- cebo Figure 1
Kaplan-Meier estimates for the probability of bleed-
ing after treatment with different concentrations of 
rThrombin or placebo. TTH was measured in the rabbit 
AV shunt model of anastomotic bleeding after treatment 
with heparin + clopidogrel. PTFE graft segments were punc-
tured, and AGS containing a standardized volume of 1000 IU/
mL or 125 IU/mL rThrombin or placebo was applied to the 
bleeding surface. The TTH observation period extended 
from 60 seconds to 300 seconds. 1000 IU/mL rThrombin: 
N = 14 grafts. 125 IU/mL rThrombin: N = 14 grafts. Placebo: 
N = 10 grafts.Annals of Surgical Innovation and Research 2009, 3:14 http://www.asir-journal.com/content/3/1/14
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presence of 125 IU/mL rThrombin (79% ruptured;
p < 0.001). The incidence of clot burst was comparable in
the presence of 125 IU/mL rThrombin (79% of clots rup-
tured) or placebo (80% ruptured). Representative images
of clots that ruptured (upper panel, 125 IU/mL
rThrombin) and clots that maintained hemostasis (lower
panel, 1000 IU/mL rThrombin) are presented in Figure 3.
Ruptured clots (top panel) have blood on the gauze
sponges and under the grafts that is not present when
hemostasis is maintained (bottom panel).
Data for body temperature, MAP, and blood flow were
collected for each graft. Statistical analysis of these data
showed that these parameters were consistently main-
tained (data not shown). Individual body weights and
aPTT values at the beginning and end of the study were
similar when compared across animals and treatment
groups. Terminal aPTT values in each animal were >
400 seconds. This represented a 2.6-fold or greater
increase in aPTT from baseline values, an expected effect
of the heparin dosing regimen.
In Vitro TEG Assays
Increasing amounts of titrated rThrombin activity led to
increased rates of clot formation (measured by the alpha
angle; Figure 4, top panel; r = 0.72; p = 0.002) and clot
strength (shear elastic modulus, defined as Gmax; Figure 4,
bottom panel; r = 0.77; p < 0.001) in
heparin + clopidogrel blood samples. In these in vitro
clotting studies, sequential increases in the amount of
rThrombin activity ultimately led to maximum (plateau)
values for the rate of clot formation and clot strength.
Discussion
Numerous factors work to reduce both endogenous and
exogenous thrombin concentration at the bleeding
wound interface, including removal and dilution by hem-
orrhagic blood flow, rapid binding to inhibitors such as
antithrombin III, entrapment in the developing throm-
bus, or mechanical removal by sponge and/or irrigation.
Whether topical thrombin is applied or not, surgeons rely
Variability in time to hemostasis (TTH) after treatment with  different concentrations of rThrombin or placebo Figure 2
Variability in time to hemostasis (TTH) after treat-
ment with different concentrations of rThrombin or 
placebo. TTH was measured in the rabbit AV shunt model 
of anastomotic bleeding after treatment with 
heparin + clopidogrel. PTFE graft segments were punctured, 
and AGS containing 1000 IU/mL or 125 IU/mL of rThrombin 
or placebo was applied to the bleeding site. The TTH obser-
vation period extended from 60 seconds to 300 seconds, as 
indicated by the dashed lines. Each diamond represents the 
TTH value for a single graft. Four grafts in the placebo group 
had not achieved hemostasis at the end of the observation 
period and are not included in the graph (i.e. 4 TTH values 
were > 300 seconds). All grafts treated with 125 IU/mL or 
1000 IU/mL rThrombin achieved hemostasis within the 
observation period.
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Clot burst assessment of AV shunt grafts treated with differ- ent concentrations of rThrombin Figure 3
Clot burst assessment of AV shunt grafts treated 
with different concentrations of rThrombin. Rabbits 
were treated with heparin + clopidogrel. The grafts were 
wrapped with AGS containing either 125 IU/mL rThrombin 
(top row) or 1000 IU/mL rThrombin (bottom row). After 
hemostasis was achieved, blood flow was clamped for 
10 seconds, and clot burst was assessed. Images were 
obtained after the 10 second assessment period. Upper 
images show sponge saturation and bleed-thru in representa-
tive grafts whose hemostasis did not survive clot burst chal-
lenge (125 IU/mL rThrombin; 11 of 14 grafts ruptured 
[79%]). Lower images show representative grafts that main-
tained hemostasis following clot burst challenge (1000 IU/mL 
rThrombin; 0 of 14 grafts ruptured [0%]). In the placebo 
group, most grafts did not maintain hemostasis (8 of 10 grafts 
ruptured [80%]; data not shown).Annals of Surgical Innovation and Research 2009, 3:14 http://www.asir-journal.com/content/3/1/14
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on intraoperative gross evaluations of hemostasis as pre-
dictors of whether hemostasis will be durable after wound
closure. When hemostasis is delayed, laboratory assess-
ments may be performed to rapidly detect any pathologic
derangements in clotting. However, the results do not
always correlate with intraoperative bleeding severity, nor
do they reliably predict response to surgical intervention
because of the many variables influencing clot formation
at the wound. We addressed several of these variables in
this study by examining the effects of rThrombin concen-
tration on hemostasis in animals treated with commonly-
administered anticoagulation agents.
Increasing concentrations of rThrombin decreased TTH in
a concentration-dependent manner in a rabbit model of
arterial bleeding. Treatment of heparinized animals with
clopidogrel delayed the onset of hemostasis. However,
treatment with rThrombin at a concentration of 1000 IU/
mL mitigated the delay in onset of hemostasis, consist-
ently providing comparable results whether animals were
treated with heparin or with heparin + clopidogrel. This
suggests that the efficacy of 1000 IU/mL rThrombin as a
topical hemostatic agent was unaffected by clopidogrel-
induced platelet inhibition. In contrast, the application of
125 IU/mL rThrombin resulted in a more variable and
delayed hemostatic response, suggesting that this concen-
tration of rThrombin was too low to reliably overcome
clopidogrel-induced platelet inhibition. This is the first
report of thrombin concentration-dependent mitigation
of the delayed hemostasis resulting from platelet inhibi-
tion. This observation lends credence to the widespread
use of topical thrombin preparations in vascular and car-
diac surgery, where platelet dysfunction is common, and
supports the proposition that use of thrombin at 1000 IU/
mL evolved because of reliable efficacy over a wide range
of clinical settings, including both pathologic and phar-
macologically-induced clotting abnormalities.
The broad utility of the 1000 IU/mL concentration of
rThrombin was further supported by an evaluation of clot
durability that was performed by clamping the graft fol-
lowing the achievement of hemostasis (clot burst testing).
Clot burst is thought to reflect the adhesiveness of the clot
boundary to the PTFE graft material, the resistance of the
clot to mechanical disruption, and indirectly, the develop-
ment of platelet force. Development of platelet force is a
process of thrombus maturation in which platelet con-
traction leads to increased fibrin strand density, thus
ensuring that a sudden increase in blood pressure does
not lead to clot failure. Normal platelet function is
required for physiologic clot initiation [18]. Furthermore,
pharmacological or mechanical inhibition of platelet
function has been associated with increased bleeding in
humans after cardiopulmonary bypass [19]. Persistent
hemostasis that resists the stresses of the early recovery
period is a desirable outcome for all surgical procedures.
We observed that clots formed in the presence of 1000 IU/
mL rThrombin were significantly more resistant to disrup-
tion than were clots formed in the presence of 125 IU/mL
rThrombin in animals treated with heparin + clopidogrel.
The disruption of clots formed in the presence of 125 IU/
mL rThrombin was indistinguishable from the disruption
of clots formed in the presence of placebo. These findings
are consistent with those of other investigators; differ-
ences in clot structure and maturation at varying
Effect of rThrombin concentration on rabbit blood throm- boelastograph (TEG) parameters Figure 4
Effect of rThrombin concentration on rabbit blood 
thromboelastograph (TEG) parameters. Blood sam-
ples were collected from study animals (N = 3) two hours 
after they had been treated with clopidogrel, and heparin was 
added to 1 U/mL. The top panel shows the alpha angle, which 
is a function of the rate of clot formation, and the bottom 
panel shows the maximum clot strength (Gmax); alpha and 
Gmax are shown over a titrated range of rThrombin activity 
that was added to the TEG reaction.Annals of Surgical Innovation and Research 2009, 3:14 http://www.asir-journal.com/content/3/1/14
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thrombin concentrations have been well described [6-8].
The fragile state of hemostasis that was achieved with
125 IU/mL human thrombin and AGS by Adams, et al.
can be better understood in light of our observations [11].
The rebleeding wounds observed at 12 minutes in the
Adams porcine hepatic bleeding model may have rebled
secondary to inadequate clot strength and density and a
higher concentration of thrombin might have resulted in
more persistent hemostasis.
Finally, results from the in vitro TEG technique are con-
sistent with prior reports that fibrin clot strength is a func-
tion of available thrombin concentration, suggesting that
there is an optimal concentration range for rThrombin
efficacy [6-8]. Although the quantities of rThrombin used
to initiate clotting in the TEG experiments cannot be
directly compared with that used for hemostasis in the
rabbit AV shunt model, increased rates of clot formation
and improved clot strength in the TEG experiments was
achieved with increasing amounts of rThrombin activity
added at the time of clot initiation. These results are also
consistent with those reported for human blood samples
in which TEG parameters increased across a 10-fold range
of rThrombin concentrations [20].
Conclusion
In an animal model of vascular bleeding, rThrombin at a
concentration of 1000 IU/mL reliably shortened TTH and
resulted in more durable hemostasis in the presence of
heparin anticoagulation and clopidogrel platelet inhibi-
tion when compared with rThrombin at a concentration
of 125 IU/mL. This observation has significant implica-
tions for current clinical practice. Increasing numbers of
patients are presenting for emergent, urgent, or elective
surgical procedures with significant clopidogrel platelet
inhibition as a result of a reluctance or inability to with-
hold clopidogrel prior to surgery. Results in this rabbit AV
shunt model suggest that topical rThrombin at a concen-
tration of 1000 IU/mL may reliably provide hemostasis in
surgical patients who have received clopidogrel, a finding
that should prompt further clinical investigation.
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